Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

OBJECTIVE: Major depressive disorder (MDD) is projected to be a leading cause of disability globally by 2030. Only a minority of patients remit with antidepressants. If assay of polymorphisms influencing central nervous system (CNS) bioavailability could guide prescribers to more effectively dose pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Psychopharmacol Neurosci
Autor principal: Singh, Ajeet B.
Format: Artigo
Idioma:Inglês
Publicat: Korean College of Neuropsychopharmacology 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4540033/
https://ncbi.nlm.nih.gov/pubmed/26243841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9758/cpn.2015.13.2.150
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars